Targeting of human epidermal growth factor receptor 2 (HER2) with trastuzumab and of vascular endothelial growth factor (VEGF) with bevacizumab in combination with chemotherapy has proven to be a milestone in molecular targeted therapy for breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.